Malcisbo AG is a renowned brand that specializes in glycoengineering technologies to develop innovative and cost-effective glycoconjugate vaccines. Founded in May 2010 as a spin-off from the Swiss Federal Institute of Technology Zurich (ETH Zurich), Malcisbo aims to tackle bacterial diseases that affect both animal health and human food safety, including zoonotic diseases. With a primary focus on preventing human Campylobacter infections, which cause food poisoning, and porcine Actinobacillus pleuropneumoniae infections, leading to economic losses in food production, Malcisbo's vaccines significantly reduce the reliance on antibiotics.

Led by a highly skilled and multidisciplinary team, Malcisbo maintains an extensive international network. The company's management board is composed of seasoned professionals with vast experience in biotech, pharma, veterinary products, and food supplements. Their commitment to innovative research and development has been recognized through various awards and grants.

Malcisbo AG is dedicated to protecting animals and humans through their cutting-edge glycoengineering technologies and novel vaccines